Approval · Notice of Compliance 11016 · 2010
SIMVASTATIN: Notice of Compliance 11016
Issued February 5, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11016
- Date
- February 5, 2010
- Company
- Meliapharm IncMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASTATIN | 02343142 | Cancelled Post Market |
| SIMVASTATIN | 02343150 | Cancelled Post Market |
| SIMVASTATIN | 02343169 | Cancelled Post Market |
| SIMVASTATIN | 02343177 | Cancelled Post Market |
| SIMVASTATIN | 02343185 | Cancelled Post Market |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB